Altre lingue Inovio Pharmaceuticals, Inc.

Azioni

INO

US45773H4092

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
10,57 ^USD	+4,40%		+9,19%	+72,71%

06/03	Transcript : Inovio Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 06, 2024
06/03	Inovio Pharmaceuticals, Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Powell Comments, Middle East Tensions in Focus as US Equity Futures Gain Pre-Bell	16/04
Inovio Pharmaceuticals Shares Slump Pre-Bell After Pricing of $36 Million Offering of Common Stock, Warrants	16/04
Top Premarket Decliners	16/04
INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants	16/04
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine	26/03
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights	07/03
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03
INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024	21/02
INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	07/02
INOVIO Reports Inducement Grant Under Inducement Plan	02/02
INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split	23/01
INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader	22/01
Inovio Pharmaceuticals, Coherus BioSciences to Collaborate on Potential Throat Cancer Treatment	04/01
INOVIO and Coherus Announces Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI?? (toripalimab-Ttzi)	04/01
Inovio Pharmaceuticals Plans BLA Submission for INO-3107 for Recurrent Respiratory Papillomatosis Treatment	03/01
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program	03/01
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program	03/01
Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) dropped from NASDAQ Biotechnology Index	15/12
Inovio: Q3 Earnings Snapshot	09/11
INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights	09/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Inovio Pharmaceuticals, Inc.

Azioni

INO

US45773H4092

Altre lingue

Filtri